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Abstract: Depression and suicide tendencies are common in chronic diseases, especially in 
epilepsy and diabetes. Suicide is one of the most important causes of death, and is usually 
underestimated. We have analyzed several studies that compare mortality as a result of suicide 
in epileptic patients and in the general population. All the studies show that epileptic patients 
have a stronger tendency toward suicide than healthy controls. Moreover it seems that some 
kinds of epilepsy have a higher risk for suicide (temporal-lobe epilepsy). Among the risk fac-
tors are surgery therapy (suicide tendency ﬁ  ve times higher than patients in pharmacological 
therapy), absence of seizures for a long time, especially after being very frequent, and psychiatric 
comorbidity (major depression, anxiety-depression disorders, personality disorders, substance 
abuse, psychoses). The aim of the review was to analyze the relationship between suicide and 
epilepsy, to identify the major risk factors, and to analyze effective treatment options.
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Introduction
Although clinicians and researchers have documented an association between epilepsy 
and psychiatric disorders for more than 30 years (Ott et al 2003), depression and other 
disorders remain underdiagnosed and undertreated in young people with epilepsy 
(Suris et al 1996; Plioplys 2003). One recent study of children of 5 to 16 years found 
that although about 60% of them had a Diagnostic and Statistical Manual of Mental 
Disorders IV (DSM) psychiatric diagnosis, only about 33% were receiving an appro-
priate psychiatric treatment (Ott et al 2003).
A paucity of published material has addressed the problem of suicide among 
epileptics. Studies on this topic have increased in recent years, but comparisons 
are difﬁ  cult because of the variety of study designs, different criteria, and different 
populations studied.
This study’s principal aims were to discuss the epidemiological data on suicide 
among epileptics, to analyze in depth the possible risk factors of suicide behavior 
in epileptic patients, and to try and develop prevention strategies for this important 
issue.
Epidemiological data
Suicide is a rare event, occurring only slightly more than once among 10,000 persons 
annually in the United States (Goodwin and Jamison 1990; Murphy 1994). A high 
suicide rate among patients with epilepsy has been documented. A Danish study 
(Henriksen et al 1970) showed that 164 of 2763 patients with epilepsy died (an excess 
mortality rate of 273% compared with the expected number of deaths in Denmark); 
the case material included all adult epileptics. Although suicide is probably not a 
major cause of death among epileptics (Hauser et al 1980; Cockell et al 1994), a 
number of investigations have reported rates of death due to suicide among individuals 
with epilepsy. The percentage of deaths by suicide ranges from 1% to 33% with an Neuropsychiatric Disease and Treatment 2008:4(2) 366
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overall average of about 11.5%. This wide range could be 
due to the different populations studied. However, Nilsson 
and colleagues’ experience of a large cohort of adults with 
epilepsy (N = 9061) is interesting. The authors identiﬁ  ed 
26 individuals with epilepsy who committed suicide and 
compared their case histories with those of 171 individuals 
with epilepsy (controls). They reported a 9-fold increase in 
the risk of suicide in the context of a mental illness and a 
10-fold increase in relative risk with the use of antipsychotic 
drugs (Nilsson et al 2002).
Many studies have reported elevated rates of suicide 
among individuals with epilepsy. In a population-based 
study, Hauser and colleagues (980) reported only 3 suicides, 
which was not above the expected number. Cockerell and 
colleagues (1994), in a population study (N = 1091), reported 
only 1 suicide during a follow-up of 6.9 (median) years. A 
group in Iceland (Rafnsson et al 2001) reported 4 suicides 
among 224 individuals with epilepsy, who were followed 
up for more than 30 years; this suicide rate was higher 
than would have been predicted. Recently, two large meta-
analyses (Pompili et al 2005, 2006) of 30 studies comprising 
51,216 people with epilepsy concluded that suicide in patients 
with epilepsy is more frequent than in the general population 
(Pompili et al 2005).
Finally, we should note the methodological issues dis-
cussed in a recently published study of mortality among epi-
leptics (Logroscino and Hesdorffer 2005): this study suggests 
that the gold standard for studies on mortality should be a 
population-based cohort of incident cases. Only this type of 
study permits a complete collection of data and the observa-
tion of the clinical phase of the disease from the diagnosis 
of epilepsy to the outcome of the study, death.
Risk factors
Predicting death caused by suicide is a nearly impossible 
task. Yet assessing suicide risk requires identiﬁ  cation of the 
factors that make individuals susceptible, and quantifying 
the individual’s level of risk.
Psychiatric comorbidity
Psychiatric comorbidity is the primary risk factor. Individuals 
with epilepsy appear to have elevated rates of Axis I disorders 
according to the DSM, ranging from 19% to 62% (Shukla 
et al 1979; Fiordelli et al 1993; Manchanda et al 1996), 
with rates of major depressive episodes from 32% to 48% 
(Blumer et al 1997; Robertson 1997; Kanner 1999; Gilliam 
et al 2002). Nilsson and colleagues (2002) have shown a 
ninefold increase in related risk of suicide associated with 
psychiatric illness and a 10-fold increase in related risk 
suicide with the intake of antipsychotic drugs.
Among epileptic patients, the most frequent diagnoses 
include affective disorders, schizophrenia, and substance 
abuse. Psychosis in particular may contribute to increased 
suicide risk: postictal psychotic episodes may increase 
the risk of suicide in individuals with epilepsy and, more 
speciﬁ  cally, individuals with temporal lobe epilepsy (TLE) 
(Mendez et al 1992; Fukuchi et al 2002).
Fukuchi and colleagues (2002) showed that three of six 
individuals with complex partial seizures who committed 
suicide did so during postictal psychotic episodes, so that 
the presence of psychotic symptoms may increase the risk 
of death by suicide among individuals with epilepsy.
Psychiatric disorders in epilepsy may result from the 
inhibitory activity that develops as a reaction to the excessive 
excitatory activity of the chronic seizure disorder (Pompili 
et al 2005, 2006).
Blumer and colleagues (2002) suggested that successful 
inhibition of psychiatric disorders could result in persistent 
suppression of seizures in chronic epilepsy, although some 
people are at risk of developing many different types of 
psychiatric complications. The relationship between epilepsy 
and psychiatric disorders is based on: (1) delay in the devel-
opment of interictal dysphoric and even more of psychotic 
disorders after onset of epilepsy, as inhibitory mechanisms 
become increasingly established; (2) as seizures decrease 
and are controlled, dysphoric symptoms and psychosis tend 
to be exacerbated or to emerge de novo (Hill 1953; Blumer 
1984; Blumer et al 2000); (3) the same psychiatric changes 
also appear at times when acute worsening of the seizures 
causes an enhanced inhibitory response, commonly in the 
prodromal and postictal phases; (4) a delay of 6–18 months 
has been noted before psychiatric changes after optimal 
surgical elimination of the epileptogenetic zone.
The acute engagement of inhibitory mechanisms by the 
seizure event tends to result in peri-ictal dysphoric symptoms 
that may include postictal depressive mood with consequent 
possible suicide.
Reports vary on the prevalence of interictal psychosis, 
but it is considered higher than the prevalence of psychosis 
in the general population (Nilsson et al 2002). Kanemoto 
and colleagues (1999) showed suicide attempts to be more 
closely associated with postictal psychosis than with inter-
ictal psychosis.
Risks for depression in epilepsy include genetic, neuro-
logic, and iatrogenic factors. A family history of depression 
is quite common among depressed patients with epilepsy. Neuropsychiatric Disease and Treatment 2008:4(2) 367
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Many of these patients report a family history of psychiatric 
illness, usually mood disorders (Kanner et al 2000).
Epilepsy and depression may share common pathogenic 
transmitter mechanisms involving decreased serotonergic, 
noradrenergic, dopaminergic, and GABAergic activity 
(Kanner et al 2002; Kanner 2005). Seizure type has been 
shown to correlate neurologically with depression, which 
is more common in patients with complex partial seizures, 
particularly those of temporal lobe origin. Most studies have 
found that depression is more common in those with left-
side foci (Mendez et al 1999) suggesting a speciﬁ  c epileptic 
psycho syndrome (Lambert et al 1986) resulting from limbic 
dysfunction. A number of antiepileptic drugs have been 
implicated in the etiology of depression, especially barbiturates 
(Lambert et al 1986; Plioplys 2003).
A chronic illness is in itself depressing and burdensome 
(Plioplys 2003). A number of factors contribute: the patient’s 
sense of having no control over seizures, the adverse effects 
of medication, the illness itself, resentment of a loss of 
independence seen in the need for life-long medication, fear 
that the stigma attached to epilepsy will interfere with social 
relationships, and anxiety about ﬁ  nances and medical insur-
ance. Teenagers and adolescents are especially concerned 
with issues related to independence (Cramer 1994).
Gender differences
Although certain gender discrepancies exist in suicidal risk 
factors, gender seems to be an important factor in predicting 
suicide. A recent study (Kalinin et al 2005) of male gender 
showed that the suicidality grade depended on the presence 
of simple partial seizures (SPS), primary generalized seizures 
(PGS), secondary generalized seizures (SGS), and complex 
partial seizure (CPS). A high degree of the ﬁ  rst three sei-
zures types determines a high degree of suicidality, while 
a large value for CPS implies, in contrast, a lower degree 
of suicidality.
The presence of the above-mentioned seizure types could 
be a trigger factor in suicide attempt decisions. On the other 
hand, these seizure types could be connected to mental dete-
rioration, itself a risk factor for suicide (Steinert et al 1994; 
Kalinin et al 2005).
A large number of generalized tonic-clonic seizures is 
considered to be a risk factor for the development of cogni-
tive impairment (Dodrill 1986; Aldenkamp 1997).
Certain discrepancies exist between men and women with 
respect to the basic characteristics of epilepsy and suicide 
rate. A risk factor for suicide in men is a high frequency of 
SGS, SPS, and all types of seizures. As most partial seizures 
have a temporal lobe origin, some authors concluded that 
temporal lobe epilepsy (TLE) in males represents a risk factor 
for suicidal behavior. Among female patients, in contrast, the 
presence of CPS is inversely correlated with death caused by 
suicide (Kalinin et al 2005).
Early age epilepsy onset means a higher risk of suicide 
in men but not in women (Kalinin et al 2005). A different 
pattern of variables was obtained for females, consisting 
mostly of values of daily doses of certain anti-epileptic drugs 
(AEDs), that is, phenobarbital PHB, carbamazepine CBZ, 
valproate VPA, clonazepam CNZ. A high daily dose of PHB 
and high total number of all seizures would imply a higher 
degree of suicidality, while the other variables, including 
daily doses of different AEDs are more ambiguous and less 
useful for suicidality prediction in women.
The prevalence of AED variables in the female gender 
can probably be explained by the behavioral toxicity of phe-
nobarbitone (PHB) and lack of toxicity during treatment with 
carbamazepine (CBZ), valplroic acid (VPA), and clonazepam 
(CNZ). In addition, PHB is regarded as a depressogenic 
drug (Reijs et al 2004), and depression, in turn, could trigger 
suicidal attempts in women.
A further study showed that daily doses of CBZ and VPA 
were negatively correlated with suicidal behavior especially 
in females who are more susceptible to depression: perhaps it 
could depend on their normotimic and antidepressive mode 
of action (Kalinin et al 2005).
The development of new AEDs has occurred during 
the past few years, which are now available to treat all 
forms of epilepsy. Among these is topiramate (Kellett et al 
1999), oxcarbazepine (Houtkooper et al 1987), gabapentin 
(Beydoun et al 1997), lamotrigine (Trenite et al 2001), 
and levetiracetam (Cramer et al 2000). Unfortunately 
little information is available on the psychiatric effects of 
these new AEDs, although probably lamotrigine’s antide-
pressant action might suggest some advantages for its use 
(Critchley 1994).
The risk of suicide in the presence of depression is ﬁ  ve-
fold higher in women and only twofold higher in men than 
in the general population (Kalinin et al 2005a, 2005b).
Concomitant cognitive deterioration and personality traits 
or so-called “enechetic constitution” and “glishroidia” have 
also been shown to be signiﬁ  cantly related to suicidal risk 
(Ritaccio et al 2001). Within each gender the presence of 
cognitive deterioration increases suicide risk approximately 
ﬁ  vefold compared with the presence of depression. In other 
words, cognitive impairment is a much stronger risk factor 
for suicide than depression in both men and women, whereas Neuropsychiatric Disease and Treatment 2008:4(2) 368
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depression remains a risk factor strictly for women but not 
for men (Kalinin et al 2005a).
Adolescence
Adolescence is a period marked by profound biological, social, 
and psychological developmental changes (Kaplan et al 1998). 
Depression and other disorders are common problems among 
adolescents (Baker 2006), but are underdiagnosed. Signs of 
depression are often dismissed as “normal” reactions in this 
age group (Lagges et al 2003) and depressed adolescents may 
appear irritated, bored, and impulsive (Brent et al 2002).
Depression is much more common in adolescents with 
chronic disease, such as diabetes and epilepsy (Brent et al 
2002; Suris et al 1996). A greater proportion of girls with 
chronic illness report feeling sad, having suicidal thoughts, 
and other symptoms of depression. In contrast, no signiﬁ  cant 
differences were seen between boys with chronic illness and 
controls, although there was a trend toward having more 
emotional problems (Suris et al 1996).
Many studies showed that onset of epilepsy in a period 
of psychosocial maturation is of greater importance than a 
long-standing illness, although the precise mechanisms lead-
ing to the increased suicide risk are not known and might 
well be multifactorial (Nilsson et al 2002).
Additional risk factors
Axis I disorders are a primary risk factor for suicide, although 
additional risk factors must be considered when conducting 
a suicide assessment. General risk factors for suicide include 
amily issues, physical health, personality, life stress, previous 
suicidal behavior, and access to ﬁ  rearms or other destructive 
means (Obfaunwa et al 1994).
A family history of suicidal behavior increases the risk of 
suicide, and the risk increases if coupled with a family history 
of affective disorder or substance abuse (Moscicki 1997).
Care should be taken to assess an individual’s perception 
of health issues, and how it might inﬂ  uence thoughts about 
the future. Individuals with epilepsy may be affected by risk 
factors such as an increase in unemployment rates and ﬁ  nan-
cial stress, and possibly increased family stress as a result of 
complications associated with a chronic medical condition 
(Robertson 1997; Jones et al 2003; Caplan et al 2005).
Table 1 summarizes the risk factors in epileptic 
patients.
Assessment
At the time of the initial diagnostic evaluation, the physi-
cian who is managing the epileptic patient should make 
a psychiatric and psychosocial assessment to identify the 
patient’s risk for suicide. This approach enables the physi-
cian to assess the effect of epilepsy on the patient and to 
detect psychiatric disorder. Effective treatment options 
include both somatic and non somatic therapies as well as 
combinations thereof.
Interventions include medications, referral to a psycholo-
gist or psychiatrist, or even hospitalization. If appropriate 
intervention can be introduced, suicide rates may be signiﬁ  -
cantly reduced (Jones et al 2003).
Greater attention is needed to other potentially self-
injurious behaviors such as willful noncompliance with 
antiepileptic drug (AED) therapy and participation in activities 
that might be considered dangerous for those with active 
epilepsy (eg, swimming, climbing) (Jones et al 2003).
A number of methods can be used to screen for suicide 
risk factors. Jones and colleagues (2003) report a useful 
instrument developed to assess individuals for psychiatric 
disorders and suicidality called MINI (Mini-International 
Neuropsychiatric Interview). The MINI module includes 
a systematic and useful series of questions that could be 
included in a clinical interview when screening for depres-
sion and psychiatric comorbidity in a busy clinical setting. 
MINI has a practical scoring system to help quantify cur-
rent suicide risk and may prove useful in determining the 
intervention required.
Further self-report measures include the Beck Depression 
Inventory, which contains suicidal ideation-related items (eg, 
question 9: “suicide thoughts and wishes”) that may prove 
useful for rapid screening.
Table 1 Risk factors for death caused by suicide in eplieptic 
patients
-Psychiatric comorbidity
Axis I
Major depression
Affective disorders
Psychoses
Substance abuse
Axis II
Personality disorders
-Cognitive deterioration
-Antiepileptic drugs
Phenobarbital
-Types of seizures
Temporal lobe epilepsy
Simple partial seizures
Primary generalized seizures
Secondary generalized seizures
-Frequency of seizures
-Early age at epilepsy onsetNeuropsychiatric Disease and Treatment 2008:4(2) 369
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Pharmacotherapy options in epileptic patients with mood 
disorders include carbamazepine and valproate, considered 
drugs of ﬁ  rst choice for their normothymic mode of action 
(Kalinin et al 2005). Giving patients AEDs which can cause 
depression, such as topiramate or levotiracetan must be 
avoided. Topiramate, in particular, has been associated with 
suicide among epileptic patients (Rejis et al 2004; Prueter 
et al 2005; Selai et al 2005).
As well as AED therapy, the antidepressant selective sero-
tonin reuptake inhibitors (SSRIs) can be used to control the 
affective aspects. However children and adolescents should 
not be given SSRIs as ﬁ  rst-line agents for mild to moderate 
depression and should be treated with nonsomatic therapies, 
especially cognitive-behavioral therapy, interpersonal psy-
chotherapy, group therapy, and psychoeducational programs 
(Baker et al 2006). The Food and Drug Administration (FDA) 
warns against the use of any SSRIs in children and adoles-
cents, and suggests that only ﬂ  uoxetine has been shown to 
be efﬁ  cacious for these patients (FDA 2005).
Conclusions
Suicide in epileptic patients is a real problem, frequently under-
diagnosed by physicians. Possible risk factors for suicide in all 
epileptic patients must always be evaluated. When one or more 
risk factors are discovered, referring physicians and families must 
try to understand the underlying causes. Few practical approaches 
are available but a combination of psychiatry, psychoeducational 
programs, and pharmacotherapy should be tried.
References
Aldenkamp A. 1997. Effect of seizures and epileptiform discharges on 
cognitive function. Epilepsia, 38(Suppl 1):S52–5.
Baker GA. 2006. Depression and suicide in adolescents with epilepsy. 
Neurology, 66(Suppl 3):S5–S12.
Beydoun A, Fischer J, Labar DR, et al. 1997. Gabapentin monotherapy: 
II. A 26-week, double-blind, dose-controlled, multicenter study of 
conversion from polytherapy in outpatients with refractory complex 
partial or secondarily generalized seizures. The US Gabapentin Study 
Group 82/83. Neurology, 49:746–52.
Blumer D, Montouris G, Davies K, et al. 2002. Suicide in epilepsy: Psycho-
pathology, pathogenesis and prevention. Epilepsy Behav, 3:232–41.
Blumer D, Altshuler L. 1997. Affective disorders. In: Engel J, Pedley TA 
eds. Epilepsy: a comprehensive textbook. Philadelphia: Lippincott-
Raven, pp. 2083–99.
Blumer D, Wakhlu S, Montouris G, et al. 2000. Treatment of the interictal 
psychoses. J Clin Psychiatry, 61:110–22.
Blumer D. 1984. Dysphoric disorders and paroxysmal affects: recognition 
and treatment of epilepsy-related psychiatric disorders. Harv Rev 
Psychiatry Pr, pp. 271–91.
Brent DA, Birmaher B. 2002. Clinical practice: adolescent depression. 
N Engl J Med, 347:667–71.
Caplan R, Siddarth P, Suresh G, et al. 2005. Depression and anxiety disorders 
in pediatric epilepsy. Epilepsia, 46:720–30.
Cockerell OC, Johnson AL, Sander JW, et al. 1994. Mortality from epilepsy: 
results from a prospective population-based study. Lancet, 344:918–21.
Cramer JA. 1994. Quality of life for people with epilepsy. Neurol Clin, 
12:1–13.
Cramer JA, Arrigo C, Van Hammee G. 2000. Effect of levetiracetam 
on epilepsy-related quality of life. N132 Study Group. Epilepsia, 
41:868–74.
Critchley MAE. 1994. Effects of lamotigine (Lamictal) in an animal model 
of anxiety. Br J Pharmacol, 111(Suppl):205P.
Dodrill C. 1986. Correlates of generalized tonic-clonic seizures with intel-
lectual, neuropsychological, emotional, and social function in patients 
with epilepsy. Epilepsia, 27:399–411.
FDA. 2005. Suicidality in children and adolescents being treated with 
antidepressant medication. FDA Public Health Advisory, October 15, 
2004 [online]. Accessed November 10, 2005. URL: http://www.fda.
gov/cder/drug/antidepressants/SSRIPHA200410.htm.
Fiordelli E, Beghi E, Bogliun G, et al. 1993. Epilepsy and psychiatric dis-
turbance: a cross-sectional study. Br J Psychiatry, 163:446–50.
Fukuchi T, Kanemoto K, Masaaki K, et al. 2002. Death in epilepsy with 
special attention to suicide cases. Epilepsy Res, 51:233–6.
Gilliam F, Kanner AM. 2002. Treatment of depressive disorders in epilepsy 
patients. Epilepsy Behav, 3:2–9.
Goodwin FK, Jamison KR. 1990. Manic-depressive illness. Oxford: Oxford 
University Press.
Hauser WA, Annegers JF, Elveback LR. 1980. Mortality in patients with 
epilepsy. Epilepsia, 21:399–412.
Henriksen B, Juul-Jensen PP, Lund M. 1970. The mortality of epileptics. 
In: Brackenridge RDC, editor. Life assurance medicine. London: 
Pitman, pp. 139–48.
Hill D. 1953. Psychiatric disorders of epilepsy. Med Press, 113:522–8.
Houtkooper MA, Lammertsma A, Meyer JW. 1987. Oxcarbazepine 
(GP 47.680): a possible alternative to carbamazepine? Epilepsy, 
28:693–8.
Jones JE, Hermann BP, Barry JJ, et al. 2003. Rates and risk factors for 
suicide, suicidal ideation, and suicide attempts in chronic epilepsy. 
Epilepsy Behav, 4:S31–S8.
Kalinin VV, Polyanskiy DA. 2005a. Gender differences in risk factors of 
suicidal behaviour in epilepsy. Epilepsy Behav, 6:424–9.
Kalinin VV, Polyanskiy DA. 2005b. Gender and suicidality prediction in 
epilepsy. Epilepsy Behav, 7:657–63.
Kanemoto K, Kawasaki J, Mori E. 1999. Violence and epilepsy: a close rela-
tion between violence and postictal psychosis. Epilepsia, 40:107–9.
Kanner AM. 2005. Depression in epilepsy: a neurobiologic perspective. 
Epilepsy Cur, 5:21–7.
Kanner AM, Balabanov A. 2002. Depression and epilepsy: how closely 
related are they? Neurology, 58:s27–39.
Kanner A, Nieto J. 1999. Depressive disorders in epilepsy. Neurology, 
53:26–32.
Kanner AM, Palac S. 2000. Depression in epilepsy: a common but often 
unrecognized comorbid malady. Epilepsy Behav, 1:37–51.
Kaplan HI, Sadock BJ. 1998. Kaplan and Sadock’s synopsis of psychiatry. 
8th ed. Philadelphia: Lippincott Williams and Wilkins.
Kellett MW, Smith DF, Stockton PA. 1999. Topiramate in clinical practice: 
ﬁ  rst year’s postlicensing experience in a specialist epilepsy clinic. 
J Neurol Neurosur Psychiatry, 66:759–63.
Lagges AM, Dunn DW. 2003. Depression in children and adolescents. 
Neurol Clin, 21:953–60.
Lambert MV, Robertson MM. 1999. Depression in epilepsy: etiology, 
phenomenology and treatment. Epilepsia, 40(Suppl 10):S21–47.
Logroscino G, Hesdorffer DC. 2005. Methodologic issues in studies of 
mortality following epilepsy: measures, types of studies, sources of 
cases, cohort effects, and competing risks. Epilepsia, 46:3–7.
Manchanda R, Schaefer B, McLachlan R. 1996. Psychiatric disorders 
in candidates for epilepsy surgery. J Neurol Neurosurg Psychiatry, 
61:82–9.
Mendez DF, Cumming JL, Benson DF. 1986. Depression in epilepsy: 
signiﬁ  cance and phenomenology. Arch Neurol, 43:766–70.
Mendez MF, Doss RC. 1992. Ictal and psychiatric aspects of suicide in 
epileptic patients. Int J Psychiatry Med, 22:231–7.Neuropsychiatric Disease and Treatment 2008:4(2) 370
Verrotti et al
Mos’cicki EK. 1997. Identiﬁ  cation of suicide risk factors using epidemiologic 
studies. Psychiat Clin North Am, 20:499–517.
Murphy GE. 1994. Suicide and attempted suicide. In: Winokur G, Clay-
ton PJ eds. The medical basis of psychiatry. Philadelphia: Saunders, 
pp. 529–44.
Nilsson L, Ahlbom A, Farahmand BY, et al. 2002. Risk factors for suicide 
in epilepsy: a case control study. Epilepsia, 43:644–51.
Obafunwa JO, Busuttil A. 1994. Clinical contact preceding suicide. Postgrad 
Med J, 70:428–32.
Ott D, Siddart P, Gurbani S, et al. 2003. Behavioral disorders in pediatric 
epielpsy: unmet psychiatric need. Epilepsia, 44:591–7.
Plioplys S. 2003. Depression in children and adolescents with epilepsy. 
Epilepsy Behav, 4:S39–S45.
Pompili M, Girardi P, Ruberto A, et al. 2005. Suicide in the epilep-
sies: a meta-analytic investigation of 29 cohorts. Epilepsy Behav, 
7:305–10.
Pompili M, Girardi P, Tatarelli R. 2006. Death from suicide versus mor-
talità from epilepsy in the epilepsies: A meta-analysis. Epilepsy Behav, 
9:641–8.
Prueter C, Norra C. 2005. Mood disorders and their treatment in patients 
with epilepsy. J Neuropsychiatry Clin Neurosci, 17:20–8.
Rafnsson V, Olafsson E, Hauser WA, et al. 2001. Cause-speciﬁ  c mortality 
in adults with unprovoked seizures: a population-based incidence cohort 
study. Neuroepidemiology, 20:232–6.
Rejis R, Aldenkamp AP, De Krom M. 2004. Mood effect of antiepileptic 
drugs. Epilepsy Behav, 5(Suppl 1):S66–76.
Ritaccio A, Devinsky O. 2001. Personality disorders in epilepsy. In: Ettinger 
AB, Kanner AM, eds. Psychiatric issues in epilepsy: a practical guide 
to diagnose and treatment. Philadelphia: Lippincott Williams and 
Wilkins, pp. 147–61.
Robertson M. 1997. Depression in neurological disorders. In: Robertson 
MM, Katona CLE eds. Depression and physical illness. Chichester: 
Wiley, pp. 305–40.
Robertson MM, Trimble MR, Townsend HRA. 1999. Phenomenology of 
depression in epilepsy. Epilepsia, 28:364–72.
Selai C, Bannister D, Trimble M. 2005. Antiepileptic drugs and the regula-
tion of mood and quality of life (QOL): the evidence from epilepsy. 
Epilepsia, 46(Suppl 4):50–7.
Shukla G, Srivastava O, Katiyar B, et al. 1979. Psychiatric manifesta-
tion in temporal lobe epilepsy: a controlled study. Br J Psychiatry, 
135:411–17.
Steinert T, Froscher W. 1994. Aggression bei Epilepsie. Nervenheikd, 13:
s199–205.
Suris JC, Parera N, Puig C. 1996. Chronic illness and emotional distress in 
adolescence. J Adolesc Health, 19:153–6.
Trenite DG, Rentmeester TW, Scholtes FB. 2001. Perimarketing surveil-
lance of lamotrigine in The Netherlands: doctor’s and patients’ view-
points. Pharm World Sci, 23:1–5.